Video
Dr. Pavic reports favorable outcomes from masitinib trial for mCRPC
Author(s):
Video Player is loading.
In this video, Michel Pavic, MD, discusses how the combination of masitinib with docetaxel could be a new first-line treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) and alkaline phosphatase levels less than or equal to 250 IU/mL. Pavic is an oncologist and head of the hematology-oncology service at CIUSSS de l’Estrie (CHUS) and a professor of medicine and health sciences at the University of Sherbrooke, Quebec, Canada.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Related Content
